Current Report Filing (8-k)
April 18 2017 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 14, 2017
RXi PHARMACEUTICALS
CORPORATION
(Exact name
of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36304
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (508) 767-3861
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
On April 18, 2017, RXi Pharmaceuticals Corporation (the
Company) issued a press release announcing that Pamela Pavco, Ph.D., Chief Development Officer and a named executive officer of the Company, had informed the Company of her intention to retire as an executive officer of the Company on
May 19, 2017. Dr. Pavco will continue her role with the Company until the effective date of her retirement and transition to the Companys Scientific Advisory Board.
In connection with Dr. Pavcos retirement, Gerrit Dispersyn, Dr. Med. Sc. has been appointed as the Chief Development Officer
of the Company effective April 24, 2017.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated April 18, 2017.
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
|
Date: April 18, 2017
|
|
|
|
By:
|
|
/s/ Geert Cauwenbergh
|
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
|
|
|
|
|
|
|
President and Chief Executive Officer
|
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Apr 2023 to Apr 2024